Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy
- PMID: 15566511
- DOI: 10.1111/j.1478-3231.2004.0956.x
Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy
Abstract
Background: Although a variety of papers demonstrated inhibited hepatocarcinogenesis with interferon (IFN) therapy for chronic hepatitis C, a small number of hepatocellular carcinomas (HCCs) were still observed even in sustained virologic responders.
Aims: To clarify factors affecting the development of HCC, we analyzed the frequency of HCC in sustained virologic responders over a long-term observation period.
Methods: Seven hundred and ninety-two out of the 2623 IFN-treated hepatitis C patients who had undergone liver biopsy showed sustained virologic response. Screening for development of HCC was performed periodically during an average follow-up of 5.1 years. Fibrosis of the pretreatment liver biopsy sample was graded. Risk factors for HCC were analyzed by using Cox proportional hazards regression.
Results: Of 792 patients, 23 developed HCC. Univariate analysis showed that stage of hepatic fibrosis, age, and alcohol consumption were significantly associated with a risk of HCC (P<0.001). There was a significant difference in the cumulative incidence between patients stratified according to these variables (P<0.001).
Conclusions: Pretreatment hepatic fibrosis score, age, and alcohol consumption may affect development of HCC even in sustained virologic responders. Thus, patients with these factors should be carefully followed even after eradication of the virus.
Similar articles
-
Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.Int J Cancer. 2000 Sep 1;87(5):741-9. Int J Cancer. 2000. PMID: 10925370
-
Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.Liver Int. 2005 Apr;25(2):247-53. doi: 10.1111/j.1478-3231.2005.1096.x. Liver Int. 2005. PMID: 15780046
-
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.Intervirology. 2007;50(1):16-23. doi: 10.1159/000096308. Intervirology. 2007. PMID: 17164553 Clinical Trial.
-
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.Clin Gastroenterol Hepatol. 2014 Jul;12(7):1186-95. doi: 10.1016/j.cgh.2013.11.033. Epub 2013 Dec 7. Clin Gastroenterol Hepatol. 2014. PMID: 24321207
-
Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.J Antimicrob Chemother. 2004 Jan;53(1):19-22. doi: 10.1093/jac/dkh031. Epub 2003 Dec 4. J Antimicrob Chemother. 2004. PMID: 14657083 Review.
Cited by
-
Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance.JGH Open. 2022 Jun 6;6(7):462-469. doi: 10.1002/jgh3.12774. eCollection 2022 Jul. JGH Open. 2022. PMID: 35822120 Free PMC article.
-
Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review.Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S245-S256. doi: 10.1093/cid/ciad380. Clin Infect Dis. 2023. PMID: 37579210 Free PMC article.
-
Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals.World J Hepatol. 2021 Nov 27;13(11):1663-1676. doi: 10.4254/wjh.v13.i11.1663. World J Hepatol. 2021. PMID: 34904036 Free PMC article. Review.
-
Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.Regen Ther. 2024 May 4;27:455-463. doi: 10.1016/j.reth.2024.04.018. eCollection 2024 Dec. Regen Ther. 2024. PMID: 38737403 Free PMC article.
-
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.World J Gastroenterol. 2007 Oct 21;13(39):5180-7. doi: 10.3748/wjg.v13.i39.5180. World J Gastroenterol. 2007. PMID: 17876888 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical